Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Thomas Look

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2020
LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotorsTing Tao, Hui Shi, Luca Mariani, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell StateNina Weichert-Leahey, Hui Shi, Ting Tao, et al.
The Journal of Clinical Investigation|May 15, 2023
Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell stateNina Weichert-Leahey, Hui Shi, Ting Tao, et al.
Haematologica|August 27, 2013
Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptorsLinda Zuurbier, Alejandro Gutierrez, Charles G Mullighan, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
Oncogene|July 31, 2021
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN lossShuning He, Mark W Zimmerman, Hillary M Layden, et al.
Oncotarget|October 6, 2016
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemiaNameeta P Richard, Raffaella Pippa, Megan M Cleary, et al.
Blood|February 4, 2010
Inactivation of LEF1 in T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Takaomi Sanda, Wenxue Ma, et al.
Cancer Cell|March 24, 2012
Activated ALK collaborates with MYCN in neuroblastoma pathogenesisShizhen Zhu, Jeong-Soo Lee, Feng Guo, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2020
LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotorsTing Tao, Hui Shi, Luca Mariani, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell StateNina Weichert-Leahey, Hui Shi, Ting Tao, et al.
The Journal of Clinical Investigation|May 15, 2023
Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell stateNina Weichert-Leahey, Hui Shi, Ting Tao, et al.
Haematologica|August 27, 2013
Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptorsLinda Zuurbier, Alejandro Gutierrez, Charles G Mullighan, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
Oncogene|July 31, 2021
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN lossShuning He, Mark W Zimmerman, Hillary M Layden, et al.
Oncotarget|October 6, 2016
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemiaNameeta P Richard, Raffaella Pippa, Megan M Cleary, et al.
Blood|February 4, 2010
Inactivation of LEF1 in T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Takaomi Sanda, Wenxue Ma, et al.
Cancer Cell|March 24, 2012
Activated ALK collaborates with MYCN in neuroblastoma pathogenesisShizhen Zhu, Jeong-Soo Lee, Feng Guo, et al.
Pageof 22